Trial reportLipids in health and disease2026
Association of fenofibrate therapy with cardiovascular events and mortality in diabetes patients with early-diagnosed hyperlipidemia.
Trial report in Lipids in health and disease, 2026. The graph read 5 numbers from its abstract, feeding 2 cells of the map: it supports the treatment in 1, finds no clear difference in 1. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
Notably, the reduction in MACEs risk was driven primarily by a significant decrease in death from cardiovascular causes among early-diagnosed hyperlipidemia group (HR 0.47, 95% CI 0.30-0.74; P for interaction = 0.07), whereas no significant benefit was observed for nonfatal myocardial infarction or stroke.
Fenofibrate significantly reduced all-cause mortality risk in the early-diagnosed group (HR = 0.57, 95% CI 0.41-0.79) but not in the late-diagnosed group (HR = 1.12, 95% CI 0.81-1.55; P for interaction = 0.006).
Similarly, fenofibrate reduced major adverse cardiovascular events (MACEs) risk in the early-diagnosed group (HR = 0.69, 95%CI 0.55-0.88), with a non-significant trend in the late-diagnosed group (HR = 0.86, 95%CI 0.64-1.16; P for interaction = 0.256).
Similarly, fenofibrate reduced major adverse cardiovascular events (MACEs) risk in the early-diagnosed group (HR = 0.69, 95%CI 0.55-0.88), with a non-significant trend in the late-diagnosed group (HR = 0.86, 95%CI 0.64-1.16; P for interaction = 0.256).
Fenofibrate significantly reduced all-cause mortality risk in the early-diagnosed group (HR = 0.57, 95% CI 0.41-0.79) but not in the late-diagnosed group (HR = 1.12, 95% CI 0.81-1.55; P for interaction = 0.006).
clause the extractor read what became the number
Where it lands on the map
Rows are treatments, columns are outcomes. The coloured squares are the cells this paper feeds, coloured by the vote it casts there. Click one to jump to what this paper adds to it.
What it adds to each cell
For every cell the paper feeds: the belief in the claim with and without this paper, and this paper's estimate drawn against every other readable study in the cell. The ringed dot is this paper.
Other lipid agents×cardiovascular events
SupportsOpen on the map →What to test next →10 readable studies in this cell: 5 favour the treatment, 5 find no difference, 0 favour the comparator.
Other lipid agents×all-cause mortality
InconclusiveOpen on the map →What to test next →2 readable studies in this cell: 1 favour the treatment, 1 find no difference, 0 favour the comparator.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The marked sentences are the ones the graph read a number from.
The age at hyperlipidemia diagnosis has been reported to be associated with cardiovascular disease and mortality. This exploratory post hoc analysis of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Lipid trial investigated whether the age at diagnosis of hyperlipidemia influences the effect of adding fenofibrate versus placebo to simvastatin on cardiovascular outcomes and all-cause mortality in diabetes patients. Participants (n = 3861) were stratified into early- (≤ 60 years old) and late-diagnosed (> 60 years old) hyperlipidemia group based on self-reported year of hyperlipidemia diagnosis. Fenofibrate significantly reduced all-cause mortality risk in the early-diagnosed group (HR = 0.57, 95% CI 0.41–0.79) but not in the late-diagnosed group (HR = 1.12, 95% CI 0.81–1.55; P for interaction = 0.006). Similarly, fenofibrate reduced major adverse cardiovascular events (MACEs) risk in the early-diagnosed group (HR = 0.69, 95%CI 0.55–0.88), with a non-significant trend in the late-diagnosed group (HR = 0.86, 95%CI 0.64–1.16; P for interaction = 0.256). Notably, the reduction in MACEs risk was driven primarily by a significant decrease in death from cardiovascular causes among early-diagnosed hyperlipidemia group (HR 0.47, 95% CI 0.30–0.74; P for interaction = 0.07), whereas no significant benefit was observed for nonfatal myocardial infarction or stroke. These findings suggest that fenofibrate use is associated with lower cardiovascular events and mortality risk specifically in diabetes patients with early-diagnosed hyperlipidemia.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.